Zealand Pharma A's ROA from the fourth quarter of 2021 to the fourth quarter of 2020 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Zealand Pharma A's ROA in the fourth quarter of 2021?
Zealand Pharma A recorded a cumulative net loss of $-162 million during 12 months ending in the fourth quarter of 2021, resulting in a negative return on assets (ROA) of -9.63%.

However, within the Healthcare sector 864 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2021 from to 5302.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2021) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Sep 30 2020) III. Quarter
Y / Y Total Assets Change	80.69 %	537.68 %	760.32 %	995.7 %	148.67 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-162	-36	-53	-53	-53
Return On Assets (TTM)	-9.63 %	-2.21 %	-4.45 %	-7.23 %	-20.25 %
ZEAL's Total Ranking	# 5302	#	#	#	# 4642
Total Assets (TTM) in million	523	2,068	2,068	2,068	290
Seq. Total Assets Change	-74.69 %	0 %	0 %	613.94 %	-10.68 %
Seq. Net Income Change	-	-	-	-	-

ZEAL's 5 Years Annual ROA >> Back to ZEAL Management Effectiveness >> Compare ZEAL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 416
Sector	# 865
Overall	# 5181

Return On Assets Statistics
High	Average	Low
48.84 %	-20.2 %	-49.24 %
(Dec 31 2018)		(Dec 31 2021)

Financial Statements
Zealand Pharma A's Assets	$ 523 million	ZEAL's Balance sheet
Zealand Pharma A's Income	$ -162 million	Quarterly ZEAL's Income Statement
ZEAL's Income by Division		See ZEAL's Income by Division

Annual Return On Assets	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018	(Dec 31 2015) FY 2017
Y / Y Total Assets Change	613.94 %	20.5 %	27.36 %	106.63 %	-
Total Assets in million	2,068	290	240	189	91
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-1,018	-130	-86	92	-18
Annual Return On Assets	-49.24 %	-44.76 %	-35.66 %	48.84 %	-19.29 %

ZEAL's 5 Years Annual ROA >> Back to ZEAL Management Effectiveness >> Compare ZEAL ROA to its Competitors

More Return On Assets Ratios
ZEAL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ZEAL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ZEAL's Competitors
Subscribers only: Roa for Zealand Pharma A's Suppliers
Subscribers only: Return On Assets for ZEAL's Customers

You may also want to know
ZEAL's Roi	ZEAL's Inventory Turnover Ratio	ZEAL's Growth Rates	ZEAL's Dividend Comparisons
	ZEAL's Profitability Ratios	ZEAL's Asset Turnover Ratio	ZEAL's Dividend Growth
ZEAL's Roe	ZEAL's Valuation Ratios	ZEAL's Financial Strength Ratios	ZEAL's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2021, within Healthcare Sector

ROA

Date modified: 2026-09-09T12:37:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.